Literature DB >> 10451687

The pathogenic consequences of a single mutated CFTR gene.

U Griesenbach1, D M Geddes, E W Alton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10451687      PMCID： PMC1765929          DOI： 10.1136/thx.54.2008.s19

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  33 in total

1.  Pulmonary function and clinical observations in men with congenital bilateral absence of the vas deferens.

Authors:  A A Colin; S M Sawyer; J E Mickle; R D Oates; A Milunsky; J A Amos
Journal:  Chest       Date:  1996-08       Impact factor: 9.410

2.  Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis.

Authors:  P W Miller; A Hamosh; M Macek; P A Greenberger; J MacLean; S M Walden; R G Slavin; G R Cutting
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

3.  Heterozygotes for the delta F508 cystic fibrosis allele are not protected against bronchial asthma.

Authors:  M Mennie; A Gilfillan; D J Brock; W A Liston
Journal:  Nat Med       Date:  1995-10       Impact factor: 53.440

4.  Cystic fibrosis mutation screening in healthy men with reduced sperm quality.

Authors:  K van der Ven; L Messer; H van der Ven; R S Jeyendran; C Ober
Journal:  Hum Reprod       Date:  1996-03       Impact factor: 6.918

5.  Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations.

Authors:  M Wilschanski; J Zielenski; D Markiewicz; L C Tsui; M Corey; H Levison; P R Durie
Journal:  J Pediatr       Date:  1995-11       Impact factor: 4.406

6.  Increased incidence of cystic fibrosis gene mutations in adults with disseminated bronchiectasis.

Authors:  P F Pignatti; C Bombieri; C Marigo; M Benetazzo; M Luisetti
Journal:  Hum Mol Genet       Date:  1995-04       Impact factor: 6.150

7.  Inflammatory cytokines in cystic fibrosis lungs.

Authors:  T L Bonfield; J R Panuska; M W Konstan; K A Hilliard; J B Hilliard; H Ghnaim; M Berger
Journal:  Am J Respir Crit Care Med       Date:  1995-12       Impact factor: 21.405

8.  Protection against bronchial asthma by CFTR delta F508 mutation: a heterozygote advantage in cystic fibrosis.

Authors:  S A Schroeder; D M Gaughan; M Swift
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

9.  Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections.

Authors:  G B Pier; M Grout; T S Zaidi; J C Olsen; L G Johnson; J R Yankaskas; J B Goldberg
Journal:  Science       Date:  1996-01-05       Impact factor: 47.728

10.  Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid.

Authors:  J J Smith; S M Travis; E P Greenberg; M J Welsh
Journal:  Cell       Date:  1996-04-19       Impact factor: 41.582
View more
  7 in total

Review 1.  Antibiotic allergy in cystic fibrosis.

Authors:  J S Parmar; S Nasser
Journal:  Thorax       Date:  2005-06       Impact factor: 9.139

2.  Higher sweat chloride levels in patients with asthma: a case-control study.

Authors:  Shally Awasthi; Pratibha Dixit; Nutan Maurya
Journal:  Indian J Pediatr       Date:  2014-05-01       Impact factor: 1.967

3.  Relationships among CFTR expression, HCO3- secretion, and host defense may inform gene- and cell-based cystic fibrosis therapies.

Authors:  Viral S Shah; Sarah Ernst; Xiao Xiao Tang; Philip H Karp; Connor P Parker; Lynda S Ostedgaard; Michael J Welsh
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-25       Impact factor: 11.205

4.  Asthma and COPD in cystic fibrosis intron-8 5T carriers. A population-based study.

Authors:  Morten Dahl; Anne Tybjaerg-Hansen; Peter Lange; Børge G Nordestgaard
Journal:  Respir Res       Date:  2005-10-09

5.  Ribosomal Stalk Protein Silencing Partially Corrects the ΔF508-CFTR Functional Expression Defect.

Authors:  Guido Veit; Kathryn Oliver; Pirjo M Apaja; Doranda Perdomo; Aurélien Bidaud-Meynard; Sheng-Ting Lin; Jingyu Guo; Mert Icyuz; Eric J Sorscher; John L Hartman; Gergely L Lukacs
Journal:  PLoS Biol       Date:  2016-05-11       Impact factor: 8.029

Review 6.  Markers of early disease and prognosis in COPD.

Authors:  Morten Dahl; Børge G Nordestgaard
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-04-15

7.  Structure-guided combination therapy to potently improve the function of mutant CFTRs.

Authors:  Guido Veit; Haijin Xu; Elise Dreano; Radu G Avramescu; Miklos Bagdany; Lenore K Beitel; Ariel Roldan; Mark A Hancock; Cecilia Lay; Wei Li; Katelin Morin; Sandra Gao; Puiying A Mak; Edward Ainscow; Anthony P Orth; Peter McNamara; Aleksander Edelman; Saul Frenkiel; Elias Matouk; Isabelle Sermet-Gaudelus; William G Barnes; Gergely L Lukacs
Journal:  Nat Med       Date:  2018-10-08       Impact factor: 53.440
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.